2.09

1.46% 0.03

After Hours: 2.20 0.11 +5.26%

Aerovate Therapeutics Inc (AVTE)

Overview News Price History Financials Discussions Forecast

Aerovate Therapeutics Inc stock is traded at $2.09, with a volume of 75,987. It is up +1.46% in the last 24 hours and up +8.29% over the past month. Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

Previous Close:

$2.06

Open:

$2.05

24h Volume:

75,987

Relative Volume:

0.17

Market Cap:

$59.76M

Revenue:

Net Income/Loss:

$-75.52M

P/E Ratio:

-0.8038

EPS:

-2.6

Net Cash Flow:

$-56.92M

1W Performance:

+10.58%

1M Performance:

+8.29%

6M Performance:

-92.93%

1Y Performance:

-84.60%

1-Day Range:

$2.03

$2.1108

1-Week Range:

$1.90

$2.1108

52-Week Range:

$1.25

$32.41

Aerovate Therapeutics Inc Stock (AVTE) Company Profile

Name

Aerovate Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

617-443-2400

Address

930 WINTER STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2024-08-12

Latest SEC Filings

AVTE's Discussions on Twitter

Aerovate Therapeutics Inc Stock (AVTE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-01-23	Initiated	Guggenheim	Buy
Dec-06-22	Upgrade	BTIG Research	Neutral → Buy
Sep-19-22	Resumed	Wedbush	Outperform
Aug-16-22	Downgrade	BTIG Research	Buy → Neutral
Feb-11-22	Initiated	BTIG Research	Buy
Jul-26-21	Initiated	Cowen	Outperform
Jul-26-21	Initiated	Evercore ISI	Outperform
Jul-26-21	Initiated	Jefferies	Buy
Jul-26-21	Initiated	Wedbush	Outperform

View All

Aerovate Therapeutics Inc Stock (AVTE) Latest News

Sep 28, 2024

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Update - Defense World

Sep 28, 2024

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Update - MarketBeat

Sep 28, 2024

Sep 26, 2024

Deerfield Management Company L.P. Series C Takes Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World

Sep 26, 2024

Deerfield Management Company L.P. Series C Acquires New Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - MarketBeat

Sep 26, 2024

Sep 25, 2024

Affinity Asset Advisors LLC Makes New $332,000 Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World

Sep 25, 2024

Sep 24, 2024

Market Highlights: Alector Inc (ALEC) Ends on a Low Note at 5.45 - The Dwinnex

Sep 24, 2024

AlgoTx completes pivotal phase 2 trial for ground-breaking CIPN treatment - PharmaTimes

Sep 24, 2024

Sep 23, 2024

AeroVironment Inc. (AVAV): Why Are Short Sellers Betting Against This Defense Tech Leader? - Insider Monkey

Sep 23, 2024

Recent Insider Activity Suggests Potential Gains for Aerovate Therapeutics Inc (AVTE) - Knox Daily

Sep 23, 2024

Sep 21, 2024

Alector (NASDAQ:ALEC) Stock Price Up 9% - Defense World

Sep 21, 2024

Sep 19, 2024

Quest Partners LLC Increases Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World

Sep 19, 2024

Alector, Inc. (NASDAQ:ALEC) Short Interest Down 5.7% in August - Defense World

Sep 19, 2024

Sep 18, 2024

Allurion Technologies Inc. (NYSE:ALUR) Short Interest Up 8.6% in August - Defense World

Sep 18, 2024

Alignment healthcare CEO sells shares worth over $1m - Investing.com

Sep 18, 2024

In the Green: Alector Inc (ALEC) Closes at 5.64, Up/Down -0.70 from Previous Day - The Dwinnex

Sep 18, 2024

Is Alector Inc (ALEC) worth investing in despite its undervalued state? - US Post News

Sep 18, 2024

Alector (NASDAQ:ALEC) Receives Overweight Rating from Cantor Fitzgerald - Defense World

Sep 18, 2024

Sep 17, 2024

Keeping an Eye on AeroVironment Inc. (AVAV) After Insider Trading Activity - Knox Daily

Sep 17, 2024

Sep 16, 2024

Prepare Yourself for Liftoff: Alector Inc (ALEC) - SETE News

Sep 16, 2024

Sep 13, 2024

Texas Permanent School Fund Corp Grows Holdings in AeroVironment, Inc. (NASDAQ:AVAV) - Defense World

Sep 13, 2024

Sep 11, 2024